US5270046A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Heparin bound anti-thrombotic material
Assignee: Ube Corp
•
Filing: 1991-11-06
•
Granted: 1993-12-14
•
Expires: 2011-11-06
Abstract
Abstract Disclosed is an anticoagulant material comprising a polymer obtained from an ionically bonded composite synthesized from i) a basic compound having a copolymerizable functional group and ii) a heparin salt. Disclosed is also a process for preparing the anticoagulant material. The anticoagulant material of the present invention can maintain excellent anticoagulant properties or antithrombotic properties over a long period of time and is capable of being applied as a component material for various medical articles such as artificial internal organs and artificial blood vessels, and a process for preparing it.
Inventors
- 👤 Nagayoshi Sakamoto
- 👤 Kazutoshi Iida
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 01:33
CPC Classifications
A; A61; A61L; A61L33/00; A61L33/0005; A61L33/0011; A61L33/0029
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
118 words
An anti-thrombotic material comprising a heparin carrying polymer formed by reacting (i) a basic monomer having a copolymerizable functional group and a functional group being capable of undergoing ionic bonding to a heparin salt; with (ii) a heparin salt, to form an ionically bonded composite with copolymerizable functional groups; and thereafter homopolymerizing the copolymerizable functional group on the ionically bonded composite or copolymerizing the same group with at least one of a hydrophilic monomer rand a hydrophobic monomer and, optionally, a cross-linking agent to form the heparin carrying polymer; and wherein the ionic bonding in said ionically bonded composite is effected in substantially ion equivalent weight and the heparin salt is not released substantially at a physiological temperature.
Claim 2
Dependent Claim
118 words
An anti-thrombotic material comprising a heparin carrying polymer formed by reacting (i) a basic monomer having a copolymerizable functional group and a functional group being capable of undergoing ionic bonding to a heparin salt; with (ii) a heparin salt, to form an ionically bonded composite with copolymerizable functional groups; and thereafter homopolymerizing the copolymerizable functional group on the ionically bonded composite or copolymerizing the same group with at least one of a hydrophilic monomer rand a hydrophobic monomer and, optionally, a cross-linking agent to form the heparin carrying polymer; and wherein the ionic bonding in said ionically bonded composite is effected in substantially ion equivalent weight and the heparin salt is not released substantially at a physiological temperature.
Claim 3
Dependent Claim
81 words
The anti-thrombotic material according to claim 1, wherein the basic compound having a copolymerizable functional group is a compound having a vinyl group, an acryloyl group or a methacryloyl group as the copolymerizable functional group, and having a tertiary amino group, a quaternary ammonium group or a quaternary pyridinium group as a basic residual group, and capable of undergoing ionic bonding to the heparin salt to form a composite that is slightly soluble in water and soluble in an organic solvent.
Claim 4
Dependent Claim
88 words
The anti-thrombotic material according to claim 1, wherein said basic compound having a copolymerizable functional group is a compound represented by the following Formula (I): ##STR4## wherein R 1 represents a hydrogen, atom or a methyl group; R 2 and R 3 may be the same or different and each represent an alkyl group having 1 to 3 carbon atoms; R 4 represents an alkyl group having 6 to 22 carbon atoms; X represents a group of negative atoms; and n represents an integer of 1 to 6.
Claim 5
Dependent Claim
34 words
The anti-thrombotic material according to claim 3, wherein the group R 4 is an alkyl group having 8 to 18 carbon atoms and the group of negative atoms represented by X is halogen atoms.
Claim 6
Dependent Claim
39 words
The anti-thrombotic material according to claim 1, wherein the heparin salt is contained in said ionically bonded composite in an amount of from 0.5 to 12% by weight as the amount of the sulfur contained in the heparin salt.
Claim 7
Dependent Claim
14 words
The anti-thrombotic material according to claim 1, wherein the heparin salt is sodium heparin.
Claim 8
Dependent Claim
41 words
The anti-thrombotic material according to claim 1, wherein said polymerizing step comprises copolymerizing the functional groups with at least one of a hydrophilic monomer and a hydrophobic monomer that are copolymerizable with the ionically bonded composite and, optionally, a cross-linking agent.
Claim 9
Dependent Claim
31 words
The anti-thrombotic material according to claim 7, wherein the anticoagulant material further comprises a polymeric compound serving as a matrix to provide the anticoagulant material with an interpenetrating or entangling construction.
Claim 10
Dependent Claim
43 words
The anti-thrombotic material according to claim 8, wherein the polymeric compound serving as a matrix is at least one selected from the group consisting of polyvinyl chloride, polyvinyl acetate, polyacrylonitrile, polyepichlorohydrin, polyurethane, polyurethaneurea, acetyl cellulose, polyhydroxyethyl acrylate, polyhydroxymethacrylate and copolymers or mixtures thereof.
Claim 11
Dependent Claim
57 words
The anti-thrombotic material according to claim 7, wherein said hydrophilic monomer that is copolymerizable with the ionically bonded composite is used and is at least one selected from the group consisting of sodium acrylate, sodium methacrylate, acrylamide, methacrylamide, N-methyl acrylamide, acrylglycine amide, hydroxyethyl acrylate, hydroxyethyl methacrylate, methoxypolyethylene glycol acrylate, methoxypolyethylene glycol methacrylate, N-vinyl-pyrrolidone, N-vinyl-lactam, and diacetone acrylamide.
Claim 12
Dependent Claim
53 words
The anti-thrombotic material according to claim 7, wherein said hydrophobic monomer that is copolymerizable with the ionically bonded composite is used and is at least one selected from the group consisting of styrene, vinyl chloride, vinyl acetate, methyl acrylate, methyl methacrylate, acrylonitrile, methacrylonitrile, alkyl-substituted styrenes, vinyl isobutyl ether, vinyl propionate, and vinyl butyrate.
Claim 13
Dependent Claim
37 words
The anti-thrombotic material according to claim 7, wherein said cross-linking agent is used and is at least one selected from the group consisting of divinylbenzene, alkylenebisacrylamides, methacrylamides, alkylene glycol diacrylates or dimethacrylates, diethylene glycol diacrylate and dimethacrylate.
References Cited (Backward Citations)
US3766104A
Cited
US3846353A
Cited
US3853804A
Cited
US3673612A
Cited
US3844989A
Cited
JPS5236779A
Cited
JPS5417797A
Cited
JPS5418317A
Cited
JPS5418518A
Cited
JPS5538964A
Cited
JPS5538963A
Cited
JPS56104670A
Cited
JPS5834494A
Cited
JPS58114013A
Cited
JPS5950335A
Cited
JPS5953058A
Cited
JPS6023626A
Cited
JPS6016260A
Cited
JPS6120309A
Cited
JPS61168355A
Cited
JPS63105767A
Cited
JPS6480368A
Cited
US5069899A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-12-13 | 1997-06-14 | 1997-12-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-12-13 | 2001-06-14 | 2001-12-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-12-13 | 2005-06-14 | 2005-12-14 | $7700.00 | Window Closed / Lapsed |